Abstract
Purpose of reviewThe aim of this study was to review imaging of myocardial hypertrophy in hypertrophic cardiomyopathy (HCM) and its phenocopies. The introduction of cardiac myosin inhibitors in HCM has emphasized the need for careful evaluation of the underlying cause of myocardial hypertrophy.Recent findingsAdvances in imaging of myocardial hypertrophy have focused on improving precision, diagnosis, and predicting prognosis. From improved assessment of myocardial mass and function, to assessing myocardial fibrosis without the use of gadolinium, imaging continues to be the primary tool in understanding myocardial hypertrophy and its downstream effects. Advances in differentiating athlete's heart from HCM are noted, and the increasing rate of diagnosis in cardiac amyloidosis using noninvasive approaches is especially highlighted due to the implications on treatment approach. Finally, recent data on Fabry disease are shared as well as differentiating other phenocopies from HCM.SummaryImaging hypertrophy in HCM and ruling out other phenocopies is central to the care of patients with HCM. This space will continue to rapidly evolve, as disease-modifying therapies are under investigation and being advanced to the clinic.
Original language | English (US) |
---|---|
Pages (from-to) | 397-404 |
Number of pages | 8 |
Journal | Current Opinion in Cardiology |
Volume | 38 |
Issue number | 5 |
DOIs | |
State | Published - Sep 1 2023 |
Keywords
- Fabry disease
- hypertrophic cardiomyopathy
- imaging
- phenocopies
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine